switching glp 1 agonists between GLP‐1 receptor in clinical practice: Expert consensus and practical guidance - Jain - 2021 - International Journal of Clinical Practice Switching from tirzepatide to retatrutide:

In a cohort of 3731 patients, weight loss of 5%, 10%, and 15% was observed in 63%, 33%, and 14%, respectively, after 56 weeks of treatment (27%, 11%, and 4% with placebo),69 or of an additional 6% at 56 weeks in patients who had already lost 6% through hypocaloric diet and exercise.70 Positive results were also observed in adolescent patients with obesity,71 and in real-life studies substantial weight loss has also been reported.7275 Phase 3 trials with GLP-1 receptor agonists indicated specifically for obesity and overweight

The administration of GLP-1RA or exendin-4 to rats fed a high-fat diet resulted in an increase in the OPG/RANKL ratio and a reduction in the degree of bone loss

Its role in gut health extends beyond glucose regulation to include mucosal barrier maintenance and intestinal immune modulation

Also promising research to show an increase in GLP-1 production

This trial underscores the expanding scope of incretin therapy beyond simple weight management, a trend also visible in the growing body of research on peptides for athletic performance and recovery

Also, in elderly diabetic patients with obesity, semaglutide therapy led to a moderate but clinically relevant reduction in BW and BMI after 3 months